Effect of escitalopram on hot flash interference: A randomized, controlled trial

Janet S. Carpenter; Katherine A. Guthrie; Joseph C. Larson; Ellen W. Freeman; Hadine Joffe; Susan D. Reed; Kristine E. Ensrud; Andrea Z. Lacroix

doi:10.1016/j.fertnstert.2012.03.001

Effect of escitalopram on hot flash interference: A randomized, controlled trial

Janet S. Carpenter, Katherine A. Guthrie, Joseph C. Larson, Ellen W. Freeman, Hadine Joffe, Susan D. Reed, Kristine E. Ensrud, Andrea Z. Lacroix

Medicine - Veteran's Administration Medical Center

Research output: Contribution to journal › Article › peer-review

33 Scopus citations

Abstract

Objective: To estimate the effect of escitalopram (10-20 mg/d) versus placebo for reducing hot flash interference in daily life and understand correlates and predictors of reductions in hot flash interference, a key measure of quality of life. Design: Multisite, randomized, double-blind, placebo-controlled clinical trial. Setting: MsFLASH clinical sites in Boston, Indianapolis, Oakland, and Philadelphia. Patient(s): A total of 205 midlife women (46% African-American) who met criteria participated. Intervention(s): After baseline, women were randomized to one pill of escitalopram 10 mg/d (n = 104) or placebo (n = 101) with follow-up at 4 and 8 weeks. At week 4, those not achieving 50% fewer hot flashes were increased to two pills daily (20 mg/d or 2 placebo pills). Main Outcome Measure(s): The Hot Flash Related Daily Interference Scale; correlates were variables from hot flash diaries; predictors were baseline demographics, clinical variables, depression, anxiety, sleep quality, and hot flashes. Result(s): Compared to placebo, escitalopram significantly reduced hot flash interference by 6.0 points at week 4 and 3.4 points at week 8 more than placebo. Reductions in hot flash interference correlated with changes in hot flash diary variables. However, baseline variables did not significantly predict reductions in hot flash interference. Conclusion(s): Escitalopram (10-20 mg/d) for 8 weeks improves women's quality of life and this benefit did not vary by demographic, clinical, mood, sleep, or hot flash variables. Clinical Trial Registration Number: NCT00894543.

Original language	English (US)
Pages (from-to)	1399-1404.e1
Journal	Fertility and Sterility
Volume	97
Issue number	6
DOIs	https://doi.org/10.1016/j.fertnstert.2012.03.001
State	Published - Jun 2012

Bibliographical note

Funding Information:
Supported by the National Institute of Aging, in collaboration with the Eunice Kennedy Shriver National Institute of Child Health and Development, the National Center for Complementary and Alternative Medicine, the Office of Research and Women's Health , and grants U01AG032656, U01AG032659, U01AG032669, U01AG032682, U01AG032699, and U01AG032700 . At Indiana, the project was supported by the Indiana Clinical and Translational Sciences Institute ( UL1 RR025761 ) from the National Center for Research Resources, Clinical and Translational Sciences Award .

Keywords

Menopause
hot flashes
night sweats
selective serotonin reuptake inhibitor

Access

10.1016/j.fertnstert.2012.03.001

OpenUrl availability

Full text

Cite this

@article{c9bea5178a9f42bd85d96834fcda1a51,

title = "Effect of escitalopram on hot flash interference: A randomized, controlled trial",

abstract = "Objective: To estimate the effect of escitalopram (10-20 mg/d) versus placebo for reducing hot flash interference in daily life and understand correlates and predictors of reductions in hot flash interference, a key measure of quality of life. Design: Multisite, randomized, double-blind, placebo-controlled clinical trial. Setting: MsFLASH clinical sites in Boston, Indianapolis, Oakland, and Philadelphia. Patient(s): A total of 205 midlife women (46% African-American) who met criteria participated. Intervention(s): After baseline, women were randomized to one pill of escitalopram 10 mg/d (n = 104) or placebo (n = 101) with follow-up at 4 and 8 weeks. At week 4, those not achieving 50% fewer hot flashes were increased to two pills daily (20 mg/d or 2 placebo pills). Main Outcome Measure(s): The Hot Flash Related Daily Interference Scale; correlates were variables from hot flash diaries; predictors were baseline demographics, clinical variables, depression, anxiety, sleep quality, and hot flashes. Result(s): Compared to placebo, escitalopram significantly reduced hot flash interference by 6.0 points at week 4 and 3.4 points at week 8 more than placebo. Reductions in hot flash interference correlated with changes in hot flash diary variables. However, baseline variables did not significantly predict reductions in hot flash interference. Conclusion(s): Escitalopram (10-20 mg/d) for 8 weeks improves women's quality of life and this benefit did not vary by demographic, clinical, mood, sleep, or hot flash variables. Clinical Trial Registration Number: NCT00894543.",

keywords = "Menopause, hot flashes, night sweats, selective serotonin reuptake inhibitor",

author = "Carpenter, {Janet S.} and Guthrie, {Katherine A.} and Larson, {Joseph C.} and Freeman, {Ellen W.} and Hadine Joffe and Reed, {Susan D.} and Ensrud, {Kristine E.} and Lacroix, {Andrea Z.}",

note = "Funding Information: Supported by the National Institute of Aging, in collaboration with the Eunice Kennedy Shriver National Institute of Child Health and Development, the National Center for Complementary and Alternative Medicine, the Office of Research and Women's Health , and grants U01AG032656, U01AG032659, U01AG032669, U01AG032682, U01AG032699, and U01AG032700 . At Indiana, the project was supported by the Indiana Clinical and Translational Sciences Institute ( UL1 RR025761 ) from the National Center for Research Resources, Clinical and Translational Sciences Award . ",

year = "2012",

month = jun,

doi = "10.1016/j.fertnstert.2012.03.001",

language = "English (US)",

volume = "97",

pages = "1399--1404.e1",

journal = "Fertility and Sterility",

issn = "0015-0282",

publisher = "Elsevier Inc.",

number = "6",

}

TY - JOUR

T1 - Effect of escitalopram on hot flash interference

T2 - A randomized, controlled trial

AU - Carpenter, Janet S.

AU - Guthrie, Katherine A.

AU - Larson, Joseph C.

AU - Freeman, Ellen W.

AU - Joffe, Hadine

AU - Reed, Susan D.

AU - Ensrud, Kristine E.

AU - Lacroix, Andrea Z.

N1 - Funding Information: Supported by the National Institute of Aging, in collaboration with the Eunice Kennedy Shriver National Institute of Child Health and Development, the National Center for Complementary and Alternative Medicine, the Office of Research and Women's Health , and grants U01AG032656, U01AG032659, U01AG032669, U01AG032682, U01AG032699, and U01AG032700 . At Indiana, the project was supported by the Indiana Clinical and Translational Sciences Institute ( UL1 RR025761 ) from the National Center for Research Resources, Clinical and Translational Sciences Award .

PY - 2012/6

Y1 - 2012/6

N2 - Objective: To estimate the effect of escitalopram (10-20 mg/d) versus placebo for reducing hot flash interference in daily life and understand correlates and predictors of reductions in hot flash interference, a key measure of quality of life. Design: Multisite, randomized, double-blind, placebo-controlled clinical trial. Setting: MsFLASH clinical sites in Boston, Indianapolis, Oakland, and Philadelphia. Patient(s): A total of 205 midlife women (46% African-American) who met criteria participated. Intervention(s): After baseline, women were randomized to one pill of escitalopram 10 mg/d (n = 104) or placebo (n = 101) with follow-up at 4 and 8 weeks. At week 4, those not achieving 50% fewer hot flashes were increased to two pills daily (20 mg/d or 2 placebo pills). Main Outcome Measure(s): The Hot Flash Related Daily Interference Scale; correlates were variables from hot flash diaries; predictors were baseline demographics, clinical variables, depression, anxiety, sleep quality, and hot flashes. Result(s): Compared to placebo, escitalopram significantly reduced hot flash interference by 6.0 points at week 4 and 3.4 points at week 8 more than placebo. Reductions in hot flash interference correlated with changes in hot flash diary variables. However, baseline variables did not significantly predict reductions in hot flash interference. Conclusion(s): Escitalopram (10-20 mg/d) for 8 weeks improves women's quality of life and this benefit did not vary by demographic, clinical, mood, sleep, or hot flash variables. Clinical Trial Registration Number: NCT00894543.

AB - Objective: To estimate the effect of escitalopram (10-20 mg/d) versus placebo for reducing hot flash interference in daily life and understand correlates and predictors of reductions in hot flash interference, a key measure of quality of life. Design: Multisite, randomized, double-blind, placebo-controlled clinical trial. Setting: MsFLASH clinical sites in Boston, Indianapolis, Oakland, and Philadelphia. Patient(s): A total of 205 midlife women (46% African-American) who met criteria participated. Intervention(s): After baseline, women were randomized to one pill of escitalopram 10 mg/d (n = 104) or placebo (n = 101) with follow-up at 4 and 8 weeks. At week 4, those not achieving 50% fewer hot flashes were increased to two pills daily (20 mg/d or 2 placebo pills). Main Outcome Measure(s): The Hot Flash Related Daily Interference Scale; correlates were variables from hot flash diaries; predictors were baseline demographics, clinical variables, depression, anxiety, sleep quality, and hot flashes. Result(s): Compared to placebo, escitalopram significantly reduced hot flash interference by 6.0 points at week 4 and 3.4 points at week 8 more than placebo. Reductions in hot flash interference correlated with changes in hot flash diary variables. However, baseline variables did not significantly predict reductions in hot flash interference. Conclusion(s): Escitalopram (10-20 mg/d) for 8 weeks improves women's quality of life and this benefit did not vary by demographic, clinical, mood, sleep, or hot flash variables. Clinical Trial Registration Number: NCT00894543.

KW - Menopause

KW - hot flashes

KW - night sweats

KW - selective serotonin reuptake inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84861580903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861580903&partnerID=8YFLogxK

U2 - 10.1016/j.fertnstert.2012.03.001

DO - 10.1016/j.fertnstert.2012.03.001

M3 - Article

C2 - 22480818

AN - SCOPUS:84861580903

SN - 0015-0282

VL - 97

SP - 1399-1404.e1

JO - Fertility and Sterility

JF - Fertility and Sterility

IS - 6

ER -

Effect of escitalopram on hot flash interference: A randomized, controlled trial

Abstract

Bibliographical note

Keywords

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this